Ying Wang1, Hui Wang1, Yiling Jiang1, Yaping Zhang1, Xiaoyan Wang2. 1. Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China. 2. Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China. Electronic address: wjj334@aol.com.
Abstract
PURPOSE: In this phase III clinical study, we assessed the clinical outcomes of combining erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with non-small-cell lung cancer (NSCLC). METHODS:Chinese NSCLC patients, who received first-line platinum-based chemotherapy but still experienced disease progression, were assigned to receive second-line treatment of erlotinib plus bevacizumab and panitumumab (arm I), or erlotinib plus placebo (arm II). The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS) and response rates. RESULTS:150 patients were enrolled in arm I, and 147 in arm II. Median PFS of arm I was 4.6 months (95% CI, 2.3-9.4 months), much longer than the median PFS in arm II (1.9 months, 95% CI 0.8-5.2 months) (P=0.003). The median OS of arm I was 10.4 months (95% CI, 7.5-13.1 months), also significantly longer than the median OS in arm II (8.9 months, 95% CI 3.3-10.9 months) (P=0.031). Partial response in arm I was 38%, significantly higher than the partial response rate of 15% in arm II (P=0.014). The occurrence rates of adverse events, including diarrhea, fatigue and rash, were higher in arm I than in arm II. CONCLUSIONS: Erlotinib plus bevacizumab and panitumumab is an efficient second-line treatment option for patients with NSCLC.
RCT Entities:
PURPOSE: In this phase III clinical study, we assessed the clinical outcomes of combining erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with non-small-cell lung cancer (NSCLC). METHODS: Chinese NSCLCpatients, who received first-line platinum-based chemotherapy but still experienced disease progression, were assigned to receive second-line treatment of erlotinib plus bevacizumab and panitumumab (arm I), or erlotinib plus placebo (arm II). The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS) and response rates. RESULTS: 150 patients were enrolled in arm I, and 147 in arm II. Median PFS of arm I was 4.6 months (95% CI, 2.3-9.4 months), much longer than the median PFS in arm II (1.9 months, 95% CI 0.8-5.2 months) (P=0.003). The median OS of arm I was 10.4 months (95% CI, 7.5-13.1 months), also significantly longer than the median OS in arm II (8.9 months, 95% CI 3.3-10.9 months) (P=0.031). Partial response in arm I was 38%, significantly higher than the partial response rate of 15% in arm II (P=0.014). The occurrence rates of adverse events, including diarrhea, fatigue and rash, were higher in arm I than in arm II. CONCLUSIONS:Erlotinib plus bevacizumab and panitumumab is an efficient second-line treatment option for patients with NSCLC.
Authors: Yang Liu; Zhi-Cheng Xiong; Xin Sun; Li Sun; Shu-Ling Zhang; Jie-Tao Ma; Cheng-Bo Han Journal: Transl Cancer Res Date: 2019-09 Impact factor: 1.241